Biomarker discovery in mass spectrometry-based urinary proteomics

Proteomics - Clinical Applications

Volumn 10, Issue 4, 2016, Pages 358-370

  Thomas, Samuel ^a   Hao, Ling ^a   Ricke, William A ^a   Li, Lingjun ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Biomarker; Mass spectrometry; Proteomics; Urine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; BLADDER TUMOR-ASSOCIATED ANTIGEN; CELL NUCLEUS ANTIGEN; FIBRIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; NUCLEAR MATRIX PROTEIN; NUMA1 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN; TIMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR ANTIGEN; TUMOR MARKER;

AFFINITY FRACTIONATION; ANALYTICAL PARAMETERS; BIOINFORMATICS; CAPILLARY ELECTROPHORESIS; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DIALYSIS; FREEZE DRYING; HUMAN; LABEL BASED QUANTIFICATION; LABEL FREE QUANTIFICATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT CUT OFF; ORTHOGONAL MODEL SYSTEM; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONCENTRATION; PROTEIN EXTRACTION; PROTEIN PRECIPITATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL DESIGN; STATISTICAL MODEL; STUDY DESIGN; ULTRAFILTRATION; URINALYSIS; URINARY PROTEOMICS; URINE; URINE COMPOSITION; ACUTE KIDNEY INJURY; DEVICES; PATHOLOGY; PROCEDURES; URINARY BLADDER NEOPLASMS;

ACUTE KIDNEY INJURY; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; BIOMARKERS; BIOMARKERS, TUMOR; FIBRIN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MASS SPECTROMETRY; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PROTEOME; PROTEOMICS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84958645720     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500102     Document Type: Review

References (137)

1. Legrain, P., Aebersold, R., Archakov, A., Bairoch, A. et al., The human proteome project: current state and future direction. Mol. Cell Proteomics 2011, 10, M111 009993.
2. Vogel, C., Marcotte, E. M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13, 227-232.
3. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T. et al., Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2, 46ps42.
4. Titz, B., Elamin, A., Martin, F., Schneider, T. et al., Proteomics for systems toxicology. Comput. Struct. Biotechnol. J. 2014, 11, 73-90.
5. Rappaport, S. M., Biomarkers intersect with the exposome. Biomarkers 2012, 17, 483-489.
6. Goodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M. et al., Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis 2015, 36, S254-S296.
7. Pavlou, M. P., Diamandis, E. P., Blasutig, I. M., The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 2013, 59, 147-157.
8. Fuzery, A. K., Levin, J., Chan, M. M., Chan, D. W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10, 13.
9. Nagaraj, N., Mann, M., Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J. Proteome Res. 2011, 10, 637-645.
10. Dudley, J. T., Butte, A. J., Identification of discriminating biomarkers for human disease using integrative network biology. Pacific Symp. Biocomput. 2009 2009, 27-38.
11. Drabovich, A. P., Martinez-Morillo, E., Diamandis, E. P., Toward an integrated pipeline for protein biomarker development. Biochim. Biophys. Acta 2015, 1854, 677-686.
12. Mischak, H., Vlahou, A., Righetti, P. G., Calvete, J. J., Putting value in biomarker research and reporting. J. Proteomics 2014, 96, A1-A3.
13. Argiles, A., Siwy, J., Duranton, F., Gayrard, N. et al., CKD273, a New proteomics classifier assessing CKD and its prognosis. Plos One 2013, 8, 1-7.
14. Zurbig, P., Jerums, G., Hovind, P., MacIsaac, R. J. et al., Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61, 3304-3313.
15. Schanstra, J. P., Zurbig, P., Alkhalaf, A., Argiles, A. et al., Diagnosis and prediction of CKD progression by assessment of urinary peptides. J. Am. Soc. Nephrol. 2015, 26, 1999-2010.
16. Zubiri, I., Posada-Ayala, M., Sanz-Maroto, A., Calvo, E. et al., Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J. Proteomics 2014, 96, 92-102.
17. Bourderioux, M., Thao, N. K., Chhuon, C., Jeanson, L. et al., A new workflow for proteomic analysis of urinary exosomes and assessment in cystinuria patients. J.Proteome Res. 2015, 14, 567-577.
18. Chen, Y. T., Chen, H. W., Domanski, D., Smith, D. S. et al., Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteomics 2012, 75, 3529-3545.
19. Carty, D. M., Siwy, J., Brennand, J. E., Zurbig, P. et al., Urinary proteomics for prediction of preeclampsia. Hypertension 2011, 57, 561-U387.
20. Roscioni, S. S., de Zeeuw, D., Hellemons, M. E., Mischak, H. et al., A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013, 56, 259-267.
21. Shi, T. J., Gao, Y. Q., Quek, S. I., Fillmore, T. L. et al., A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J. Proteome Res. 2014, 13, 875-882.
22. Barratt, J., Topham, P., Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007, 177, 361-368.
23. Decramer, S., de Peredo, A. G., Breuil, B., Mischak, H. et al., Urine in clinical proteomics. Mol. Cell. Proteomics 2008, 7, 1850-1862.
24. Jia, L., Zhang, L., Shao, C., Song, E. et al., An attempt to understand kidney's protein handling function by comparing plasma and urine proteomes. PLoS One 2009, 4, e5146.
25. Saritas, T., Kuppe, C., Moeller, M. J., Progress and controversies in unraveling the glomerular filtration mechanism. Curr. Opin. Nephrol. Hypertens. 2015, 24, 208-216.
26. Tojo, A., Kinugasa, S., Mechanisms of glomerular albumin filtration and tubular reabsorption. Int. J. Nephrol. 2012, 2012, 481520.
27. Baker, E. S., Liu, T., Petyuk, V. A., Burnum-Johnson, K. E. et al., Mass spectrometry for translational proteomics: progress and clinical implications. Genome Med. 2012, 4, 63.
28. Zurbig, P., Decramer, S., Dakna, M., Jantos, J. et al., The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009, 9, 2108-2117.
29. Macoska, J. A., Kasina, S., Campeau, L., Andersson, K.-E., Geriatric Urology, Springer, New York 2014, pp. 13-35.
30. Adeola, H. A., Soares, N. C., Paccez, J. D., Kaestner, L. et al., Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry. Proteomics Clin. Appl. 2015, 9, 597-609.
31. Maes, E., Cho, W. C., Baggerman, G., Translating clinical proteomics: the importance of study design. Expert. Rev. Proteomics 2015, 12, 217-219.
32. Cairns, D. A., Barrett, J. H., Billingham, L. J., Stanley, A. J. et al., Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics 2009, 9, 74-86.
33. Levin, Y., The role of statistical power analysis in quantitative proteomics. Proteomics 2011, 11, 2565-2567.
34. Oberg, A. L., Vitek, O., Statistical design of quantitative mass spectrometry-based proteomic experiments. J. Proteome Res. 2009, 8, 2144-2156.
35. Dakna, M., Harris, K., Kalousis, A., Carpentier, S. et al., Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010, 11, 594.
36. Bossuyt, P. M., Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326, 41-44.
37. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E. et al., Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005, 97, 1180-1184.
38. von Elm, E., Altman, D. G., Egger, M., Pocock, S. J. et al., The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370, 1453-1457.
39. Dudley, J. T., Tibshirani, R., Deshpande, T., Butte, A. J., Disease signatures are robust across tissues and experiments. Mol. Syst. Biol. 2009, 5, 307.
40. Lee, G., Singanamalli, A., Wang, H., Feldman, M. D. et al., Supervised multi-view canonical correlation analysis (sMVCCA): integrating histologic and proteomic features for predicting recurrent prostate cancer. IEEE Trans. Med. Imaging 2015, 34, 284-297.
41. Nawaz, M., Camussi, G., Valadi, H., Nazarenko, I. et al., The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat. Rev. Urol. 2014, 11, 688-701.
42. Patel, S., Ngounou Wetie, A. G., Darie, C. C., Clarkson, B. D., Cancer secretomes and their place in supplementing other hallmarks of cancer. Adv. Exp. Med. Biol. 2014, 806, 409-442.
43. Thomas, C. E., Sexton, W., Benson, K., Sutphen, R., Koomen, J., Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 953-959.
44. Jackson, D. H., Banks, R. E., Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin. Appl. 2010, 4, 250-270.
45. Lee, R. S., Monigatti, F., Briscoe, A. C., Waldon, Z. et al., Optimizing sample handling for urinary proteomics. J. Proteome Res. 2008, 7, 4022-4030.
46. Afkarian, M., Bhasin, M., Dillon, S. T., Guerrero, M. C. et al., Optimizing a proteomics platform for urine biomarker discovery. Mol. Cell Proteomics 2010, 9, 2195-2204.
47. Hepburn, S., Cairns, D. A., Jackson, D., Craven, R. A. et al., An analysis of the impact of pre-analytical factors on the urine proteome: sample processing time, temperature, and proteolysis. Proteomics Clin. Appl. 2015, 9, 507-521.
48. Greer, T., Hao, L., Nechyporenko, A., Lee, S. et al., Custom 4-Plex DiLeu Isobaric labels enable relative quantification of urinary proteins in men with lower urinary tract symptoms (LUTS). Plos One 2015, 10, 1-20.
49. Santucci, L., Candiano, G., Petretto, A., Bruschi, M. et al., From hundreds to thousands: widening the normal human Urinome (1). J. Proteomics 2015, 112, 53-62.
50. Olszowy, P., Buszewski, B., Urine sample preparation for proteomic analysis. J. Sep. Sci. 2014, 37, 2920-2928.
51. Feist, P., Hummon, A. B., Proteomic challenges: sample preparation techniques for microgram-quantity protein analysis from biological samples. Int. J. Mol. Sci. 2015, 16, 3537-3563.
52. Simpson, D. M., Beynon, R. J., Acetone precipitation of proteins and the modification of peptides. J. Proteome Res. 2010, 9, 444-450.
53. Cunningham, R., Wang, J. X., Wellner, D., Li, L. J., Investigation and reduction of sub-microgram peptide loss using molecular weight cut-off fractionation prior to mass spectrometric analysis. J. Mass Spectrom. 2012, 47, 1327-1332.
54. Greening, D. W., Simpson, R. J., A centrifugal ultrafiltration strategy for isolating the low-molecular weight (
55. Wisniewski, J. R., Zougman, A., Nagaraj, N., Mann, M., Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6, 359-362.
56. Wisniewski, J. R., Ostasiewicz, P., Mann, M., High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J. Proteome Res. 2011, 10, 3040-3049.
57. Erde, J., Loo, R. R., Loo, J. A., Enhanced FASP (eFASP) to increase proteome coverage and sample recovery for quantitative proteomic experiments. J. Proteome Res. 2014, 13, 1885-1895.
58. Yu, Y., Suh, M. J., Sikorski, P., Kwon, K. et al., Urine sample preparation in 96-well filter plates for quantitative clinical proteomics. Anal. Chem. 2014, 86, 5470-5477.
59. Gutstein, H. B., MorriS, J. S., Annangudi, S. P., Sweedler, J. V., Microproteomics: analysis of protein diversity in small samples. Mass Spectrom. Rev. 2008, 27, 316-330.
60. Anderson, N. L., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
61. Millioni, R., Tolin, S., Puricelli, L., Sbrignadello, S. et al., High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011, 6, e19603.
62. Fiedler, G. M., Baumann, S., Leichtle, A., Oltmann, A. et al., Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2007, 53, 421-428.
63. Filip, S., Vougas, K., Zoidakis, J., Latosinska, A. et al., Comparison of depletion strategies for the enrichment of low-abundance proteins in urine. PLoS One 2015, 10, e0133773.
64. Castagna, A., Cecconi, D., Sennels, L., Rappsilber, J. et al., Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 2005, 4, 1917-1930.
65. Candiano, G., Dimuccio, V., Bruschi, M., Santucci, L. et al., Combinatorial peptide ligand libraries for urine proteome analysis: investigation of different elution systems. Electrophoresis 2009, 30, 2405-2411.
66. Pant, S., Hilton, H., Burczynski, M. E., The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol. 2012, 83, 1484-1494.
67. Dear, J. W., Street, J. M., Bailey, M. A., Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling. Proteomics 2013, 13, 1572-1580.
68. Alvarez, M. L., Khosroheidari, M., Ravi, R. K., DiStefano, J. K., Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012, 82, 1024-1032.
69. Pisitkun, T., Shen, R. F., Knepper, M. A., Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 2004, 101, 13368-13373.
70. Pitto, M., Corbetta, S., Raimondo, F., Preparation of urinary exosomes: methodological issues for clinical proteomics. Methods Mol. Biol. 2015, 1243, 43-53.
71. Megger, D. A., Bracht, T., Meyer, H. E., Sitek, B., Label-free quantification in clinical proteomics. Biochim. Biophys. Acta 2013, 1834, 1581-1590.
72. Buchberger, A., Yu, Q., Li, L., Advances in mass spectrometric tools for probing neuropeptides. Ann. Rev. Anal. Chem. 2015, 8, 485-509.
73. Adeola, H. A., Soares, N. C., Paccez, J. D., Kaestner, L. et al., Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry. Proteomics Clin. Appl. 2015, 9, 597-609.
74. Duan, X., Young, R., Straubinger, R. M., Page, B. et al., A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J. Proteome Res. 2009, 8, 2838-2850.
75. Sandin, M., Chawade, A., Levander, F., Is label-free LC-MS/MS ready for biomarker discovery? Proteomics Clin. Appl. 2015, 9, 289-294.
76. Han, D. K., Eng, J., Zhou, H. L., Aebersold, R., Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 2001, 19, 946-951.
77. Ji, C. J., Guo, N., Li, L., Differential dimethyl labeling of N-termini of peptides after guanidination for proteome analysis. J. Proteome Res. 2005, 4, 2099-2108.
78. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S., Heck, A. J. R., Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protocols 2009, 4, 484-494.
79. Ross, P. L., Huang, Y. L. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
80. Jing, L. H., Parker, C. E., Seo, D., Hines, M. W. et al., Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. Proteomics 2011, 11, 2763-2776.
81. Thompson, A., Schafer, J., Kuhn, K., Kienle, S. et al., Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 2003, 75, 1895-1904.
82. Sinclair, J., Timms, J. F., Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods 2011, 54, 361-369.
83. Hung, C. W., Tholey, A., Tandem mass tag protein labeling for top-down identification and quantification. Anal. Chem. 2012, 84, 161-170.
84. Murphy, J. P., Everley, R. A., Coloff, J. L., Gygi, S. P., Combining amine metabolomics and quantitative proteomics of cancer cells using derivatization with isobaric tags. Anal. Chem. 2014, 86, 3585-3593.
85. Xiang, F., Ye, H., Chen, R. B., Fu, Q., Li, L. J., N, N-Dimethyl leucines as novel isobaric tandem mass tags for quantitative proteomics and peptidomics. Anal. Chem. 2010, 82, 2817-2825.
86. Frost, D. C., Greer, T., Xiang, F., Liang, Z., Li, L., Development and characterization of novel 8-plex DiLeu isobaric labels for quantitative proteomics and peptidomics. Rapid Commun. Mass Spectrom. 2015, 29, 1115-1124.
87. Frost, D. C., Greer, T., Li, L. J., High-resolution enabled 12-Plex DiLeu isobaric tags for quantitative proteomics. Anal. Chem. 2015, 87, 1646-1654.
88. Greer, T., Lietz, C. B., Xiang, F., Li, L. J., Novel isotopic N, N-dimethyl leucine (iDiLeu) reagents enable absolute quantification of peptides and proteins using a standard curve approach. J. Am. Soc. Mass Spectrom. 2015, 26, 107-119.
89. Hao, L., Zhong, X. F., Greer, T., Ye, H., Li, L. J., Relative quantification of amine-containing metabolites using isobaric N, N-dimethyl leucine (DiLeu) reagents via LC-ESI-MS/MS and CE-ESI-MS/MS. Analyst 2015, 140, 467-475.
90. Choe, L., D'Ascenzo, M., Relkin, N. R., Pappin, D. et al., 8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007, 7, 3651-3660.
91. Rauniyar, N., Gao, B. B., McClatchy, D. B., Yates, J. R., Comparison of protein expression ratios observed by sixplex and duplex TMT labeling method. J. Proteome Res. 2013, 12, 1031-1039.
92. Werner, T., Becher, I., Sweetman, G., Doce, C. et al., High-resolution enabled TMT 8-plexing. Anal. Chem. 2012, 84, 7188-7194.
93. Everley, R. A., Kunz, R. C., McAllister, F. E., Gygi, S. P., Increasing throughput in targeted proteomics assays: 54-plex quantitation in a single mass spectrometry run. Anal. Chem. 2013, 85, 5340-5346.
94. Robinson, R. A. S., Evans, A. R., Enhanced sample multiplexing for nitrotyrosine-modified proteins using combined precursor isotopic labeling and isobaric tagging. Anal. Chem. 2012, 84, 4677-4686.
95. McAlister, G. C., Huttlin, E. L., Haas, W., Ting, L. et al., Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Anal. Chem. 2012, 84, 7469-7478.
96. Hebert, A. S., Merrill, A. E., Bailey, D. J., Still, A. J. et al., Neutron-encoded mass signatures for multiplexed proteome quantification. Nat. Methods 2013, 10, 332.
97. Hebert, A. S., Merrill, A. E., Stefely, J. A., Bailey, D. J. et al., Amine-reactive neutron-encoded labels for highly plexed proteomic quantitation. Mol. Cell. Proteomics 2013, 12, 3360-3369.
98. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
99. Huttenhain, R., Malmstrom, J., Picotti, P., Aebersold, R., Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 2009, 13, 518-525.
100. Zangar, R. C., Daly, D. S., White, A. M., ELISA microarray technology as a high-throughput system for cancer biomarker validation. Expert. Rev. Proteomic 2006, 3, 37-44.
101. Makawita, S., Diamandis, E. P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 2010, 56, 212-222.
102. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 2011, 29, 635-U119.
103. Barnidge, D. R., Goodmanson, M. K., Klee, G. G., Muddiman, D. C., Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 2004, 3, 644-652.
104. Li, W. L., Nemirovskiy, O., Fountain, S., Mathews, W. R., Szekely-Klepser, G., Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: a biomarker of matrix metalloproteinase activity and osteoarthritis in human urine. Anal. Biochem. 2007, 369, 41-53.
105. Simon, R., Lemoine, J., Fonbonne, C., Jaffuel, A. et al., Absolute quantification of podocin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-multiple reaction monitoring cubed mass spectrometry. J. Pharmaceut. Biomed. Anal. 2014, 94, 84-91.
106. Kirkpatrick, D. S., Gerber, S. A., Gygi, S. P., The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35, 265-273.
107. DeSouza, L. V., Taylor, A. M., Li, W., Minkoff, M. S. et al., Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J. Proteome Res. 2008, 7, 3525-3534.
108. Yoon, J. Y., Yeom, J., Lee, H., Kim, K. et al., High-throughput peptide quantification using mTRAQ reagent triplex. BMC Bioinformatics 2011, 12, 1-12.
109. Yin, H. R., Zhang, L., Xie, L. Q., Huang, L. Y. et al., Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. J. Proteome Res. 2013, 12, 3912-3919.
110. Elias, J. E., Haas, W., Faherty, B. K., Gygi, S. P., Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat. Methods 2005, 2, 667-675.
111. Mischak, H., Delles, C., Klein, J., Schanstra, J. P., Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv. Chronic Kidney D 2010, 17, 493-506.
112. Coon, J. J., Zurbig, P., Dakna, M., Dominicza, A. F. et al., CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2008, 2, 964-973.
113. Pejchinovski, M., Hrnjez, D., Ramirez-Torres, A., Bitsika, V. et al., Capillary zone electrophoresis on-line coupled to mass spectrometry: a perspective application for clinical proteomics. Proteomics Clin. Appl. 2015, 9, 453-468.
114. Airoldi, L., Magagnotti, C., Iannuzzi, A. R., Marelli, C. et al., Effects of cigarette smoking on the human urinary proteome. Biochem. Bioph. Res. Co. 2009, 381, 397-402.
115. Fliser, D., Novak, J., Thongboonkerd, V., Argiles, A. et al., Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 2007, 18, 1057-1071.
116. Klein, J., Papadopoulos, T., Mischak, H., Mullen, W., Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis 2014, 35, 1060-1064.
117. Angel, T. E., Aryal, U. K., Hengel, S. M., Baker, E. S. et al., Mass spectrometry-based proteomics: existing capabilities and future directions. Chem. Soc. Rev. 2012, 41, 3912-3928.
118. Thongboonkerd, V., Songtawee, N., Sritippayawan, S., Urinary proteome profiling using microfluidic technology on a chip. J. Proteome Res. 2007, 6, 2011-2018.
119. Sajic, T., Liu, Y., Aebersold, R., Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin. Appl. 2015, 9, 307-321.
120. Egertson, J. D., MacLean, B., Johnson, R., Xuan, Y., MacCoss, M. J., Multiplexed peptide analysis using data-independent acquisition and Skyline. Nat. Protoc. 2015, 10, 887-903.
121. Schubert, O. T., Gillet, L. C., Collins, B. C., Navarro, P. et al., Building high-quality assay libraries for targeted analysis of SWATH MS data. Nat. Protoc. 2015, 10, 426-441.
122. Thiese, M. S., Arnold, Z. C., Walker, S. D., The misuse and abuse of statistics in biomedical research. Biochem. Med. 2015, 25, 5-11.
123. Swan, A. L., Mobasheri, A., Allaway, D., Liddell, S., Bacardit, J., Application of machine learning to proteomics data: classification and biomarker identification in postgenomics biology. OMICS 2013, 17, 595-610.
124. Carnielli, C. M., Winck, F. V., Paes Leme, A. F., Functional annotation and biological interpretation of proteomics data. Biochim. Biophys. Acta 2015, 1854, 46-54.
125. Mi, H., Muruganujan, A., Casagrande, J. T., Thomas, P. D., Large-scale gene function analysis with the PANTHER classification system. Nat. Protoc. 2013, 8, 1551-1566.
126. Frantzi, M., Bhat, A., Latosinska, A., Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin. Transl. Med. 2014, 3, 7.
127. Acosta-Martin, A. E., Lane, L., Combining bioinformatics and MS-based proteomics: clinical implications. Expert. Rev. Proteomics 2014, 11, 269-284.
128. Griss, J., Perez-Riverol, Y., Hermjakob, H., Vizcaino, J. A., Identifying novel biomarkers through data mining-a realistic scenario? Proteomics Clin. Appl. 2015, 9, 437-443.
129. Mischak, H., Kolch, W., Aivaliotis, M., Bouyssie, D. et al., Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin. Appl. 2010, 4, 464-478.
130. Taylor, C. F., Paton, N. W., Lilley, K. S., Binz, P.-A. et al., The minimum information about a proteomics experiement (MIAPE). Nat. Biotechnol. 2007, 25, 887-893.
131. Taylor, C. F., Binz, P.-A., Aebersold, R., Affolter, M. et al., Guidelines for reporting the use of mass spectrometry in proteomics. Nat. Biotechnol. 2008, 26, 860-861.
132. Gu, Q., Yu, L. R., Proteomics quality and standard: from a regulatory perspective. J. Proteomics 2014, 96, 353-359.
133. Anderson, L., Six decades searching for meaning in the proteome. J. Proteomics 2014, 107, 24-30.
134. Barr, A., Wall Street Journal (Online), New York, NY 2014.
135. Mapes, M., Endocrine News, Endocrine Society, Washington DC 2015, pp. 44-45.
136. Carr, S. A., Anderson, L., Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin. Chem. 2008, 54, 1749-1752.
137. Endre, Z. H., Pickering, J. W., Cell cycle arrest biomarkers win race for AKI diagnosis. Nat. Rev. Nephrol. 2014, 10, 685-686.